NASDAQ:RPRX Royalty Pharma (RPRX) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free RPRX Stock Alerts $30.59 +0.14 (+0.46%) (As of 09:47 AM ET) Add Compare Share Share Today's Range$30.49▼$30.6850-Day Range$27.71▼$31.3352-Week Range$25.92▼$37.31Volume124,497 shsAverage Volume2.64 million shsMarket Capitalization$18.28 billionP/E Ratio16.19Dividend Yield2.75%Price Target$52.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Royalty Pharma alerts: Email Address Royalty Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside71.6% Upside$52.25 Price TargetShort InterestHealthy3.34% of Float Sold ShortDividend StrengthModerateBased on Four FactorsSustainability-2.25Upright™ Environmental ScoreNews Sentiment0.86Based on 4 Articles This WeekInsider TradingSelling Shares$7.69 M Sold Last QuarterProj. Earnings Growth9.74%From $3.90 to $4.28 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.99 out of 5 starsFinance Sector4th out of 863 stocksPharmaceutical Preparations Industry3rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingRoyalty Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.25, Royalty Pharma has a forecasted upside of 71.6% from its current price of $30.45.Amount of Analyst CoverageRoyalty Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.34% of the float of Royalty Pharma has been sold short.Short Interest Ratio / Days to CoverRoyalty Pharma has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Royalty Pharma has recently decreased by 3.66%, indicating that investor sentiment is improving. Previous Next 2.5 Dividend Strength Dividend YieldRoyalty Pharma pays a meaningful dividend of 2.78%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthRoyalty Pharma has only been increasing its dividend for 4 years.Dividend CoverageThe dividend payout ratio of Royalty Pharma is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Royalty Pharma will have a dividend payout ratio of 19.63% next year. This indicates that Royalty Pharma will be able to sustain or increase its dividend. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRoyalty Pharma has received a 47.64% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Rotavirus vaccine", "HIV medication", "Breast cancer medication", "Prostate cancer medication", "Rheumatoid arthritis medication", and "Multiple myeloma medication" products. See details.Environmental SustainabilityThe Environmental Impact score for Royalty Pharma is -2.25. Previous Next 3.3 News and Social Media Coverage News SentimentRoyalty Pharma has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Finance companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Royalty Pharma this week, compared to 4 articles on an average week.Search Interest22 people have searched for RPRX on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat Follows23 people have added Royalty Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 130% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Royalty Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,691,494.00 in company stock.Percentage Held by Insiders18.72% of the stock of Royalty Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.35% of the stock of Royalty Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.8 Earnings and Valuation Earnings GrowthEarnings for Royalty Pharma are expected to grow by 9.74% in the coming year, from $3.90 to $4.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Royalty Pharma is 16.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.41.Price to Earnings Ratio vs. SectorThe P/E ratio of Royalty Pharma is 16.11, which means that it is trading at a less expensive P/E ratio than the Finance sector average P/E ratio of about 57.65.Price to Earnings Growth RatioRoyalty Pharma has a PEG Ratio of 0.87. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioRoyalty Pharma has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Royalty Pharma Stock (NASDAQ:RPRX)Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Read More RPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPRX Stock News HeadlinesMarch 27, 2024 | investorplace.comThe Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your PortfolioMarch 23, 2024 | americanbankingnews.comRoyalty Pharma (NASDAQ:RPRX) Downgraded to Hold at StockNews.comMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:March 16, 2024 | ca.finance.yahoo.comRPRX Dec 2024 17.500 callMarch 16, 2024 | ca.finance.yahoo.comRPRX Oct 2024 40.000 putMarch 11, 2024 | msn.comFDA rejects Viatris/Mapi long-acting version of Teva's CopaxoneMarch 7, 2024 | nasdaq.comNotable Two Hundred Day Moving Average Cross - RPRXFebruary 28, 2024 | finance.yahoo.comRoyalty Pharma to Present at TD Cowen’s 44th Annual Health Care ConferenceMarch 28, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 28, 2024 | globenewswire.comRoyalty Pharma to Present at TD Cowen's 44th Annual Health Care ConferenceFebruary 19, 2024 | uk.news.yahoo.comEntertainment firm director hauled before courts for breaking rulesFebruary 18, 2024 | finance.yahoo.comAnalysts Have Made A Financial Statement On Royalty Pharma plc's (NASDAQ:RPRX) Yearly ReportFebruary 17, 2024 | finance.yahoo.comRoyalty Pharma Full Year 2023 Earnings: EPS: US$2.54 (vs US$0.098 in FY 2022)February 16, 2024 | markets.businessinsider.comGoldman Sachs Reaffirms Their Buy Rating on Royalty Pharma (RPRX)February 16, 2024 | msn.comRoyalty Pharma (RPRX) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesFebruary 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Royalty Pharma on Strong Financials and Growth ProspectsFebruary 16, 2024 | finance.yahoo.comRoyalty Pharma plc (NASDAQ:RPRX) Q4 2023 Earnings Call TranscriptFebruary 16, 2024 | msn.comWall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 MonthsFebruary 16, 2024 | fool.comWall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 MonthsFebruary 16, 2024 | finance.yahoo.comRoyalty Pharma PLC (RPRX): A Strategic SWOT InsightFebruary 15, 2024 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma Reports Q4 and Full Year 2023 ResultsFebruary 15, 2024 | finance.yahoo.comRoyalty Pharma Reports Q4 and Full Year 2023 ResultsFebruary 15, 2024 | finance.yahoo.comRoyalty Pharma PLC (RPRX) Earnings Report: A Detailed AnalysisFebruary 15, 2024 | seekingalpha.comRoyalty Pharma plc 2023 Q4 - Results - Earnings Call PresentationFebruary 15, 2024 | globenewswire.comRoyalty Pharma Reports Q4 and Full Year 2023 ResultsFebruary 14, 2024 | benzinga.comRoyalty Pharma's Earnings: A PreviewFebruary 7, 2024 | msn.comRoyalty Pharma Backs MorphoSys’s Acquisition with Strategic InvestmentSee More Headlines Receive RPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Ex-Dividend for 3/15 Dividend2/15/2024Dividend Payable3/15/2024Today3/27/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:RPRX CUSIP76028H20 CIK897075 Webwww.royaltypharma.com Phone212-883-0200FaxN/AEmployees51Year Founded1996Price Target and Rating Average Stock Price Target$52.25 High Stock Price Target$60.00 Low Stock Price Target$42.00 Potential Upside/Downside+71.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.89 Trailing P/E Ratio16.11 Forward P/E Ratio7.81 P/E Growth0.87Net Income$1.13 billion Net Margins48.22% Pretax Margin72.20% Return on Equity26.93% Return on Assets15.93% Debt Debt-to-Equity Ratio0.61 Current Ratio7.90 Quick Ratio7.90 Sales & Book Value Annual Sales$2.36 billion Price / Sales7.72 Cash Flow$4.59 per share Price / Cash Flow6.63 Book Value$16.88 per share Price / Book1.80Miscellaneous Outstanding Shares597,430,000Free Float485,595,000Market Cap$18.19 billion OptionableOptionable Beta0.45 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Pablo Gerardo Legorreta (Age 59)Founder, Chairman of the Board & CEO Mr. Terrance P. CoyneExecutive VP & CFOMr. George Wingate Lloyd (Age 65)Executive VP of Investments & Chief Legal Officer Comp: $4.35MMr. Christopher Hite (Age 57)Vice Chairman & Executive VP Comp: $4.35MDr. Marshall Urist M.D.Ph.D., Executive VP and Head of Research & InvestmentsMr. Arthur R. McGivern J.D.Executive Vice President of Investments & General CounselMr. Ashwin Pai M.D.Executive Vice President of InvestmentsMs. Kristin Stafford (Age 41)Senior VP & Chief Accounting Officer Mr. Eric SchneiderSenior VP & Chief Technology OfficerDr. James Folmar Reddoch Ph.D. (Age 54)Executive VP of Investments & Chief Scientific Officer Comp: $3.4MMore ExecutivesKey CompetitorsRegions FinancialNYSE:RFNorthern TrustNASDAQ:NTRSShinhan Financial GroupNYSE:SHGCorebridge FinancialNYSE:CRBGKENYSE:BEKEView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Bought 5,438 shares on 3/22/2024Ownership: 0.002%Vanguard Group Inc.Sold 1,439,832 shares on 3/11/2024Ownership: 6.360%Wellington Management Group LLPSold 51,461 shares on 3/5/2024Ownership: 0.007%Goldman Sachs Group Inc.Sold 1,340,649 shares on 3/1/2024Ownership: 0.480%Geo Capital Gestora de Recursos LtdSold 46,826 shares on 2/27/2024Ownership: 0.015%View All Insider TransactionsView All Institutional Transactions Should I Buy Royalty Pharma Stock? RPRX Pros and Cons Explained These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Royalty Pharma was last updated on Wednesday, March 27, 2024 at 11:06 PM. Pros Here are some ways that investors could benefit from investing in Royalty Pharma plc: Royalty Pharma plc operates as a buyer of biopharmaceutical royalties, providing a unique investment opportunity in the biopharmaceutical industry. The company collaborates with innovators from various sectors, including academic institutions, research hospitals, and biotechnology companies, enhancing its potential for growth and innovation. Identifying, evaluating, and acquiring royalties on biopharmaceutical therapies can lead to a diversified revenue stream for the company, potentially reducing investment risk. Recent positive developments in the biopharmaceutical industry have increased the demand for innovative therapies, potentially benefiting Royalty Pharma plc's portfolio. Considering the current stock price and market trends, investing in Royalty Pharma plc may offer a favorable entry point for investors seeking exposure to the biopharmaceutical sector. Cons Investors should be bearish about investing in Royalty Pharma plc for these reasons: Market volatility and regulatory changes in the biopharmaceutical industry can impact the company's revenue streams and profitability. Competition in the biopharmaceutical royalty market may pose challenges for Royalty Pharma plc in acquiring lucrative royalties and maintaining growth. Fluctuations in biopharmaceutical research and development trends could affect the company's ability to identify and acquire royalties on successful therapies. External economic factors, such as interest rate changes or global market conditions, may influence the company's financial performance and stock valuation. Investors should carefully assess the company's financial reports, market positioning, and industry outlook before making investment decisions in Royalty Pharma plc. RPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Royalty Pharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RPRX shares. View RPRX analyst ratings or view top-rated stocks. What is Royalty Pharma's stock price target for 2024? 4 brokerages have issued 1 year price targets for Royalty Pharma's shares. Their RPRX share price targets range from $42.00 to $60.00. On average, they anticipate the company's stock price to reach $52.25 in the next year. This suggests a possible upside of 71.6% from the stock's current price. View analysts price targets for RPRX or view top-rated stocks among Wall Street analysts. How have RPRX shares performed in 2024? Royalty Pharma's stock was trading at $28.09 at the beginning of 2024. Since then, RPRX shares have increased by 8.4% and is now trading at $30.45. View the best growth stocks for 2024 here. When is Royalty Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RPRX earnings forecast. How were Royalty Pharma's earnings last quarter? Royalty Pharma plc (NASDAQ:RPRX) issued its earnings results on Thursday, February, 15th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.03 by $0.12. The biopharmaceutical company earned $736 million during the quarter, compared to the consensus estimate of $702.90 million. Royalty Pharma had a trailing twelve-month return on equity of 26.93% and a net margin of 48.22%. How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma? Royalty Pharma declared a quarterly dividend on Friday, January 19th. Investors of record on Friday, February 16th will be given a dividend of $0.21 per share on Friday, March 15th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.76%. The ex-dividend date is Thursday, February 15th. This is a boost from the stock's previous quarterly dividend of $0.20. Read our dividend analysis for RPRX. Is Royalty Pharma a good dividend stock? Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.84 per share and currently has a dividend yield of 2.78%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 44.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RPRX will have a dividend payout ratio of 19.63% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RPRX. What ETFs hold Royalty Pharma's stock? ETFs with the largest weight of Royalty Pharma (NASDAQ:RPRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), iShares U.S. Pharmaceuticals ETF (IHE), Formidable ETF (FORH), Fidelity Disruptive Medicine ETF (FMED), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Victoryshares Free Cash Flow ETF (VFLO), VictoryShares Nasdaq Next 50 ETF (QQQN) and Invesco Nasdaq Biotechnology ETF (IBBQ). What other stocks do shareholders of Royalty Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO). When did Royalty Pharma IPO? Royalty Pharma (RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers. Who are Royalty Pharma's major shareholders? Royalty Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (6.36%), Vanguard Group Inc. (6.36%), Baillie Gifford & Co. (2.94%), Viking Global Investors LP (1.69%), Norges Bank (0.71%) and Legal & General Group Plc (0.49%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Avara Management Ltd, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston and Terrance P Coyne. View institutional ownership trends. How do I buy shares of Royalty Pharma? Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RPRX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.